Robert W. Baird Reiterates “Outperform” Rating for Amicus Therapeutics, Inc. (FOLD)

Robert W. Baird reiterated their outperform rating on shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in a report published on Wednesday. Robert W. Baird currently has a $18.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $16.00.

A number of other research analysts also recently commented on the stock. J P Morgan Chase & Co reaffirmed an overweight rating on shares of Amicus Therapeutics in a research report on Wednesday. Leerink Swann reaffirmed a buy rating and set a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday. Bank of America Corporation boosted their price objective on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the company a buy rating in a research report on Wednesday. Cowen and Company reaffirmed an outperform rating and set a $18.00 price objective (up from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, September 14th. Finally, Chardan Capital reaffirmed a buy rating and set a $16.50 price objective (down from $17.50) on shares of Amicus Therapeutics in a research report on Wednesday, September 13th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Amicus Therapeutics has a consensus rating of Buy and a consensus target price of $18.07.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded down 5.76% during trading on Wednesday, hitting $15.06. 3,920,960 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $14.11 and its 200 day moving average is $10.59. The firm’s market capitalization is $2.48 billion. Amicus Therapeutics has a 1-year low of $4.41 and a 1-year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The firm had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. During the same period in the previous year, the firm posted ($0.40) earnings per share. On average, equities research analysts forecast that Amicus Therapeutics will post ($1.32) earnings per share for the current year.

WARNING: “Robert W. Baird Reiterates “Outperform” Rating for Amicus Therapeutics, Inc. (FOLD)” was reported by BBNS and is the sole property of of BBNS. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://baseballnewssource.com/markets/robert-w-baird-reiterates-outperform-rating-for-amicus-therapeutics-inc-fold/1699789.html.

In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of the firm’s stock in a transaction on Thursday, July 13th. The stock was bought at an average cost of $12.25 per share, with a total value of $18,375,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.40% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Teacher Retirement System of Texas grew its position in Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 169 shares in the last quarter. Principal Financial Group Inc. grew its position in Amicus Therapeutics by 1.8% in the first quarter. Principal Financial Group Inc. now owns 26,883 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 487 shares in the last quarter. KCG Holdings Inc. grew its position in Amicus Therapeutics by 1.1% in the first quarter. KCG Holdings Inc. now owns 66,066 shares of the biopharmaceutical company’s stock worth $471,000 after acquiring an additional 743 shares in the last quarter. Legal & General Group Plc grew its position in Amicus Therapeutics by 1.6% in the second quarter. Legal & General Group Plc now owns 55,411 shares of the biopharmaceutical company’s stock worth $558,000 after acquiring an additional 852 shares in the last quarter. Finally, Amalgamated Bank grew its position in Amicus Therapeutics by 5.7% in the second quarter. Amalgamated Bank now owns 18,451 shares of the biopharmaceutical company’s stock worth $186,000 after acquiring an additional 1,002 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.